Cloudbyz

JULY 31, 2024

The landscape of modern medicine is rapidly evolving, driven by groundbreaking advancements in diagnostics. This revolution is enabling the growth of innovative biomarker-based precision medicine and cell and gene therapy, transforming both clinical research and post-market care.

Gene Therapy 52

Gene Therapy Gene Medicine In-Vitro 52

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” . PLYMOUTH MEETING, Pa. , PLYMOUTH MEETING, Pa. , mg and 2.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

JANUARY 26, 2024

This technology, which allows for precise editing of DNA at specific locations, has been a major focus in the field due to its potential to directly target and modify cancer-causing genes. Personalized medicine: One of the most exciting prospects of CRISPR/Cas9 in oncology is its contribution to personalized medicine.

Research 118

Research Gene Editing Gene Genetics 118

XTalks

JANUARY 19, 2024

Radiobiological and Clinical Considerations from CRO and Emerging Biotech Radiopharmaceuticals are medicinal formulations containing radioisotopes that are used in the field of nuclear medicine primarily for the diagnosis and treatment of various diseases, particularly cancer. There have been more than $1.7

DNA 66

DNA Radiology FDA Approval Development 66

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.

Licensing 52

Licensing Licensing Medicine Development 52

XTalks

NOVEMBER 7, 2022

Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The cfDNA that originates from tumors is called circulating tumor DNA (ctDNA). FoundationOne ® Liquid CDx (Foundation Medicine; end-to-end commercial provider).

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Worldwide Clinical Trials

JULY 8, 2024

In nuclear medicine, radiopharmaceuticals play a pivotal role in two primary applications: Diagnostic Imaging Radiopharmaceuticals are administered to patients, where they accumulate in specific organs or tissues of interest.

Hormones 130

Hormones Regulation Clinical Trials Clinical Trials 130